Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548548 · ClinicalTrials.gov registry record · Phase 3
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 774
- Enrollment target
NCT00548548 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 774 participants.
The verdict
NCT00548548, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 774 participants
- Enrollment target
Study Summary
This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or metastatic gastric cancer who had not received prior chemotherapy for advanced or metastatic disease.
Interventions
- DRUG Bevacizumab
- DRUG Placebo
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG 5-fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 774 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548548
The ClinicalTrials.gov registry entry for NCT00548548 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 774 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00548548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548548 about?
NCT00548548 is a clinical study titled "A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer". This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or metastatic gastric cancer who had not received prior chemotherapy for advanced o...
What is the current status of trial NCT00548548?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 774 participants. The study started on 2007-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00548548?
The interventions under investigation include: Bevacizumab (DRUG), Placebo (DRUG), Capecitabine (DRUG), Cisplatin (DRUG), 5-fluorouracil (DRUG).
Who is sponsoring clinical trial NCT00548548?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.